Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons
I give below details of changes in the Directors' interests in the Ordinary Shares and American Depositary Shares (ADSs) of GlaxoSmithKline plc.
On 31 December 2013, the Company's Non-Executive Directors were allocated notional Ordinary Shares at a price of £16.07 per Ordinary Share, and notional ADSs at a price of $53.17 per ADS under the share allocation arrangements for Non-Executive Directors for the period of service from 1 October 2013 to 31 December 2013:
Non Executive Director |
Ordinary Shares |
American Depositary Shares (ADSs) |
|
|
|
Sir Christopher Gent |
2,644.680 |
|
|
|
|
Professor Sir Roy Anderson |
563.939 |
|
|
|
|
Dr Stephanie Burns |
|
320.928 |
|
|
|
Stacey Cartwright |
447.262 |
|
|
|
|
Lynn Elsenhans |
|
577.671 |
|
|
|
Judy Lewent |
|
311.489 |
|
|
|
Sir Deryck Maughan |
|
868.394 |
|
|
|
Dr Daniel Podolsky |
|
651.295 |
|
|
|
Tom de Swaan |
408.370 |
|
|
|
|
Jing Ulrich |
|
217.098 |
|
|
|
Hans Wijers |
447.262 |
|
|
|
|
Sir Robert Wilson |
447.262 |
|
|
|
|
The Company and the Non-Executive Directors were informed of these allocations on 2 January 2014.
This notification relates to transactions notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Sonja Arsenić
Corporate Secretariat
3 January 2014